

# **Revlimid - (5, 10, 15, 25 mg; Capsule, Oral)**

| Generic Name          | Lenalidomide   | Innovator            | Celgene             |
|-----------------------|--|----------------------|---------------------|
| Dosage                | 5, 10, 15, 25 mg; Capsule, Oral  | Branded US Sales     | More Than \$1000 mn |
| Probable FTF          | Less Than 5  | Known Para IV Filers | More Than 5         |
| Other ANDA developers | More Than 5  | Tentative Approvals  | Less Than 5         |
| Final Approvals       | More Than 5  | Generic Launches     | More Than 5         |
| Indication            | Indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. |                      |                     |
| Complexities          | Yes  |                      |                     |

### **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

### **Executive Summary**

Please Contact  $\underline{contact@researchdelta.com}$  to get Detailed Information.

#### **Patent Status**

Please Contact contact@researchdelta.com to get Detailed Information.

## **Launch Timelines and Competition**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

## **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.



# Revlimid - (2.5, 20 mg; Capsule)

| Generic Name          | Lenalidomide  | Innovator            | Celgene             |
|-----------------------|---|----------------------|---------------------|
| Dosage                | 2.5, 20 mg; Capsule   | Branded US Sales     | Less Than \$1000 mn |
| Probable FTF          | Less Than 5   | Known Para IV Filers | More Than 5         |
| Other ANDA developers | More Than 5   | Tentative Approvals  | Less Than 5         |
| Final Approvals       | More Than 5   | Generic Launches     | More Than 5         |
| Indication            | REVLIMID is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities |                      |                     |
| Complexities          | Yes   |                      |                     |

### **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

### **Executive Summary**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.

#### **Patent Status**

Please Contact  $\underline{contact@researchdelta.com}$  to get Detailed Information.

### **Launch Timelines and Competition**

Please Contact  $\underline{contact@researchdelta.com}$  to get Detailed Information.

## **Chronology Of Events**

Please Contact <a href="mailto:contact@researchdelta.com">contact@researchdelta.com</a> to get Detailed Information.